Entero Therapeutics (ENTO) Competitors $0.53 -0.02 (-3.48%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsShort InterestTrends ENTO vs. PHIO, TLPH, BCDA, INDP, CDT, ENSC, MYNZ, SPRC, BFRI, and CYCNShould you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include Phio Pharmaceuticals (PHIO), Talphera (TLPH), BioCardia (BCDA), Indaptus Therapeutics (INDP), Conduit Pharmaceuticals (CDT), Ensysce Biosciences (ENSC), Mainz Biomed (MYNZ), SciSparc (SPRC), Biofrontera (BFRI), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry. Entero Therapeutics vs. Phio Pharmaceuticals Talphera BioCardia Indaptus Therapeutics Conduit Pharmaceuticals Ensysce Biosciences Mainz Biomed SciSparc Biofrontera Cyclerion Therapeutics Phio Pharmaceuticals (NASDAQ:PHIO) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, community ranking, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability. Does the MarketBeat Community favor PHIO or ENTO? Phio Pharmaceuticals received 36 more outperform votes than Entero Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformPhio PharmaceuticalsOutperform Votes3663.16% Underperform Votes2136.84% Entero TherapeuticsN/AN/A Does the media prefer PHIO or ENTO? In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 1 mentions for Phio Pharmaceuticals and 0 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 0.00 beat Phio Pharmaceuticals' score of -0.12 indicating that Entero Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Phio Pharmaceuticals Neutral Entero Therapeutics Neutral Which has more volatility and risk, PHIO or ENTO? Phio Pharmaceuticals has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, Entero Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Do analysts rate PHIO or ENTO? Phio Pharmaceuticals presently has a consensus target price of $36.00, suggesting a potential upside of 1,482.42%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Phio Pharmaceuticals is more favorable than Entero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PHIO or ENTO more profitable? Entero Therapeutics' return on equity of -87.06% beat Phio Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Phio PharmaceuticalsN/A -134.57% -108.39% Entero Therapeutics N/A -87.06%-12.01% Which has better earnings and valuation, PHIO or ENTO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhio PharmaceuticalsN/AN/A-$10.83M-$10.92-0.21Entero TherapeuticsN/AN/A-$15.80MN/AN/A Do insiders & institutionals have more ownership in PHIO or ENTO? 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 0.6% of Phio Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Entero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryPhio Pharmaceuticals beats Entero Therapeutics on 9 of the 12 factors compared between the two stocks. Get Entero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTO vs. The Competition Export to ExcelMetricEntero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.50M$6.56B$5.41B$9.25BDividend YieldN/A2.96%5.37%3.99%P/E RatioN/A9.8988.9917.55Price / SalesN/A337.821,229.4079.77Price / CashN/A64.1243.6036.96Price / Book0.235.115.024.73Net Income-$15.80M$154.90M$117.89M$224.61M7 Day Performance-6.23%1.79%2.12%1.76%1 Month Performance-16.35%1.93%4.08%5.37%1 Year PerformanceN/A5.10%26.88%21.70% Entero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTOEntero TherapeuticsN/A$0.51-6.6%N/AN/A$2.42MN/A0.009PHIOPhio Pharmaceuticals2.4668 of 5 stars$6.60+290.5%$36.00+445.5%-59.2%$9.85MN/A-0.6010News CoverageGap UpHigh Trading VolumeTLPHTalphera3.4037 of 5 stars$0.58-4.0%$4.50+681.0%-28.4%$9.81M$281,000.00-0.8419Analyst ForecastNews CoverageBCDABioCardia3.5063 of 5 stars$2.25+5.6%$25.00+1,011.1%-66.7%$9.75M$71,000.00-0.5440Positive NewsGap DownINDPIndaptus Therapeutics3.1998 of 5 stars$0.950.0%$8.50+794.9%-51.0%$9.69MN/A-0.566CDTConduit PharmaceuticalsN/A$0.09-24.4%N/A-97.6%$9.59MN/A0.003News CoverageGap UpENSCEnsysce Biosciences0.0151 of 5 stars$7.17-4.3%N/A-53.2%$9.36M$2.23M-0.2610News CoverageGap UpMYNZMainz Biomed2.2838 of 5 stars$4.67+9.1%$120.00+2,469.6%-88.7%$9.35M$917,203.00-0.0730News CoveragePositive NewsGap UpSPRCSciSparc0.4788 of 5 stars$0.85+4.9%N/A-83.8%$8.85M$1.75M0.004Gap UpBFRIBiofrontera3.1385 of 5 stars$1.13+0.9%$7.00+519.5%-37.8%$8.76M$35.36M-0.5070News CoveragePositive NewsCYCNCyclerion TherapeuticsN/A$3.23-1.8%N/A-18.9%$8.75M$1.62M0.0030Positive NewsGap Up Related Companies and Tools Related Companies Phio Pharmaceuticals Competitors Talphera Competitors BioCardia Competitors Indaptus Therapeutics Competitors Conduit Pharmaceuticals Competitors Ensysce Biosciences Competitors Mainz Biomed Competitors SciSparc Competitors Biofrontera Competitors Cyclerion Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ENTO) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behi...Porter & Company | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENTO Stock Alerts